These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 19077713)

  • 1. Advances in the use of biologic agents for the treatment of systemic vasculitis.
    Chung SA; Seo P
    Curr Opin Rheumatol; 2009 Jan; 21(1):3-9. PubMed ID: 19077713
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the B cell in vasculitis.
    Walsh M; Jayne D
    Pediatr Nephrol; 2009 Jul; 24(7):1267-75. PubMed ID: 18931860
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment of ANCA-associated vascularitides].
    Guillevin L; Pagnoux C
    Presse Med; 2007 May; 36(5 Pt 2):922-7. PubMed ID: 17408912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ANCA-associated vasculitides: pathogenetic aspects and current evidence-based therapy.
    Holle JU; Gross WL
    J Autoimmun; 2009; 32(3-4):163-71. PubMed ID: 19345067
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Vasculitis management: discovery of antineutrophil cytoplasmic antibodies (ANCA)].
    Guillevin L
    Presse Med; 2007 May; 36(5 Pt 2):843-4. PubMed ID: 17449373
    [No Abstract]   [Full Text] [Related]  

  • 6. Update on the use of biologics in vasculitides.
    Vishwanath S; Relan M; Shen L; Ambrus JL
    Curr Pharm Biotechnol; 2014; 15(6):558-62. PubMed ID: 25213365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Biotherapies to treat necrotizing vasculitis].
    Guillevin L
    Rev Med Interne; 2010 Dec; 31 Suppl 3():S304-6. PubMed ID: 21055849
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of refractory and/or severe ANCA-associated systemic necrotizing vasculitides.
    Guillevin L; Pagnoux C
    Isr Med Assoc J; 2008 Jan; 10(1):89-91. PubMed ID: 18300585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Role of biologic therapy in systemic autoimmune diseases].
    Espinosa G; Cervera R
    Med Clin (Barc); 2007 Mar; 128(12):456-7. PubMed ID: 17408539
    [No Abstract]   [Full Text] [Related]  

  • 10. B cell targeted therapies in autoimmune diseases.
    Isenberg DA
    J Rheumatol Suppl; 2006 May; 77():24-8. PubMed ID: 16652442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic strategies for systemic necrotizing vasculitides.
    Guillevin L; Pagnoux C
    Allergol Int; 2007 Jun; 56(2):105-11. PubMed ID: 17460440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biological therapies: new treatment options for ANCA-associated vasculitis?
    Aries PM; Lamprecht P; Gross WL
    Expert Opin Biol Ther; 2007 Apr; 7(4):521-33. PubMed ID: 17373903
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary systemic vasculitis: treatment of difficult cases.
    Foster R; Rosenthal E; Marques S; Vounotrypidis P; Sangle S; D'Cruz D
    Lupus; 2006; 15(3):143-7. PubMed ID: 16634367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rituximab in the treatment of anti-neutrophil cytoplasm antibody associated vasculitis and systemic lupus erythematosus: past, present and future.
    Walsh M; Jayne D
    Kidney Int; 2007 Sep; 72(6):676-82. PubMed ID: 17609693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on the management of systemic vasculitis: what did we learn in 2009?
    Hellmich B
    Clin Exp Rheumatol; 2010; 28(1 Suppl 57):98-103. PubMed ID: 20412713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutaneous dermatomyositis in the era of biologicals.
    Wright NA; Vleugels RA; Callen JP
    Semin Immunopathol; 2016 Jan; 38(1):113-21. PubMed ID: 26563285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Biologic therapies in the systemic vasculitides].
    Díaz-Orta MA; Rojas-Serrano J
    Reumatol Clin; 2011 Dec; 7 Suppl 3():S33-6. PubMed ID: 22152288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacological therapy of vasculitis: an update.
    Uthman I
    Curr Opin Pharmacol; 2004 Apr; 4(2):177-82. PubMed ID: 15063363
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perspective on future therapy of vasculitis.
    Boumpas DT; Kritikos HD; Daskalakis NG
    Curr Rheumatol Rep; 2000 Oct; 2(5):423-9. PubMed ID: 11123093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Twenty-seven years' activities of the French vasculitis study group (FVSG)].
    Guillevin L
    Rev Med Interne; 2007 Dec; 28 Suppl 4():S263-5. PubMed ID: 18029060
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.